Skip to main content
SpringerLink
Log in

Methods for Detection of Minimal Residual Disease

  • Conference paper
Acute Leukemias VI

Part of the book series: Haematology and Blood Transfusion / Hämatologie und Bluttransfusion ((HAEMATOLOGY,volume 38))

Abstract

The available treatment strategies for patients with leukemia results in a high complete remission rate, defined as <5% detectable neoplastic cells by light-microscopic examination. However, many patients will eventually relapse due to persistence of low numbers of malignant cells that are undetectable by conventional cytomorphological techniques whose detection limit is 1-5 leukemic cells among 100 normal cells. The leukemic cell load under this level is called “minimal residual disease” (MRD). Owing to this patients are indiscriminately subjected to post-remission treatment to eliminate MRD, with the risk of certain cases being either underand over-treated. Therefore, more sensitive techniques for detection of lower frequencies of leukemic cells are needed [1, 2]. These will allow us to evaluate the effectiveness of treatment through a more precise assessment of the tumor mass in order to predict impending relapses prior to clinical manifestations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. San Miguel JF, C. Bartram, D. Campana, M. Andreeff. Minimal residual disease in hematological malignancies. Rev. Inv. Clin (Suppl) 1994; 147–152.

    Google Scholar 

  2. Worman B, S. Konemans, M. Safford, et al. Immunophenotypic heterogeneity of leukemic cell in AML at diagnosis and after chemotherapy. Blood 1990; 76: 377a.

    Google Scholar 

  3. Bennett JM. Detection of relapse in acute leukemia: should we discontinue routine bone marrow serveillance?. Leukemia 1992; 6: 1099–1110.

    PubMed  CAS  Google Scholar 

  4. Dewald GW, M.A. Morris, V.C. Lilla. Chromosome studies in neoplastic hematological disorders. In: Clinical Laboratory Medicine, KD McClatchey, ed. Williams & Wilkins, Baltimore (1993).

    Google Scholar 

  5. Criel A, I. Wlodarska, P. Meeus, M. Stul, A. Louwagie, V. Hoof, M. Hudajat, C. Mecucci, H. Van den Berghe. Trisomy 12 is uncommon in typical chronic lymphocytic leukaemias. Br. J. Haematol. 1994; 87: 523–528.

    Article  PubMed  CAS  Google Scholar 

  6. Kibbelaar RE, F. Kok, E.J. Dreef, J.K. Kleiverda, C.J. Cornelisse, A.K. Kaap, PhM. Kluin. Statistical methods in interphase cytogenetics: an experimental approach. Cytometry 1993; 14: 716–724.

    Article  PubMed  CAS  Google Scholar 

  7. Tkachuk CD, C.A. Westbrook, M. Andreeff, et al. Detection of bcr-abl fusion in chronic myelogenous leukemia by in-situ hybridization. Science 1990; 250: 559–562.

    Article  PubMed  CAS  Google Scholar 

  8. Kibbelaar, R.E. H. van Camp. D.J. Dreef, et al. Combined immunophenotyping and DNA in situ hybridization study lineage involvement in patients with myelodysplastic syndromes. Blood 1992; 79: 1823–1828.

    PubMed  CAS  Google Scholar 

  9. Uckun FM, J.H. Kersey, R. Haake, et al. Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia. N.Engl.J.Med. 1993; 329: 1296–1301.

    Article  PubMed  CAS  Google Scholar 

  10. Gerhartz MM, H. Schmetzer. Detection of minimal residual disease in acute myeloid leukemia. Leukemia 1990; 4: 508–516.

    PubMed  CAS  Google Scholar 

  11. Miller CB. B.A. Zehnbaner. S. Piantadosi. S.D. Rowley, and R.J. Jones. Correlation of occult clonogenic leukemia drug sensitivity with relapse after autologous bone marrow transplantation. Blood 1991; 78: 1125–1131.

    PubMed  CAS  Google Scholar 

  12. Estrov Z, T. Gunberger, I.D. Dube, Y-P. Wang, M.H. Freedman: Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained in remission. N.Engl.J.Med. 1986; 315: 386–389.

    Article  Google Scholar 

  13. Aul C, N. Gutterman, W. Schneider: Comparison of in vitro growth characteristics of blast cell progenitors (CFU-L) in patients with myelodysplastic syndromes and acute leukemia. Blood 1992; 80: 625–633.

    PubMed  CAS  Google Scholar 

  14. Orfao A, J. Ciudad, M.C. López-Berges, A. López Borrasca, B. Vidriales, M.D. Caballero, B. Valverde, M. Gonzalez, J.F. San Miguel. Acute lymphoblastic leukemia (ALL): detection of minimal residual disease (MRD) at flow cytometry. Leukemia & Lymphoma 1994; 1:87–90.

    Article  Google Scholar 

  15. Campana D, E. Coustan-Smith, G. Janossy. The immunological detection of minimal residual disease in acute leukemia. Blood 1990; 76: 163–169.

    PubMed  CAS  Google Scholar 

  16. Campana D, E. Coustan-Smith, F.G. Behm. The definition of remission in acute leukemia with immunologic techniques. B.M.T. 1991; 8: 429–437.

    CAS  Google Scholar 

  17. Van Dongen JJM, T.M. Breit, H.J. Adriaansen, A. Beishuizen, H. Hooijkaas. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia 1992; 6: 47–59.

    PubMed  Google Scholar 

  18. Worman B. Implications of detection of minimal residual disease. Current Opinion in Oncology 1993; 5: 3–12.

    Google Scholar 

  19. Adriaansen HJ, B.C. Jacobs, M.C. Kappers-Klunne, K. Hanle, H. Hooijkaas, J.J.M. van Dongen. Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers. Leukemia 1993; 7: 472–481.

    PubMed  CAS  Google Scholar 

  20. Hooijkaas H, K. Hahlen, H.J. Adriaansen, I. Dekker, G.E. van Zanen, J.J.M. van Dongen. Terminal deoxynucleotidyl transferase (TdT)-positive cells in the cerebrospinal fluid and development of overt CNS leukemia: a 5-year follow-up study in 113 child r e n with a TdT-positive leukemia or non-Hodgkin’s lymphoma. Blood 1989; 74: 416–422.

    PubMed  CAS  Google Scholar 

  21. Campana D, S. Yokota, E. Coustant-Smith, T.E. Hansen-Hagge, G. Janossy, C.R. Bartram. The detection of residual acute lymphoblastic leukemia cells with immunologic methods and polymerase chain reaction: a compartive study. Leukemia 1990; 9: 609–614.

    Google Scholar 

  22. Coustant-Smith E, F.G. Behm, C.A. Hurwitz, G.K.J. Rivera, D. Campana. N-CAM (CD56) expression by CD34+ malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia. Leukemia 1993; 7: 853–858.

    Google Scholar 

  23. Macedo A, A. Orfao, M.B. Vidriales, M.C. López-Berges, B. Valverde, M. Gonzalez, M.D. Caballero, F. Ramos, M. Martinez, J.F. San Miguel. Characterization of aberrant fenotypes in acute myeloid leukemia. Ann.Hematol. 1995; 70: 189–194.

    Article  PubMed  CAS  Google Scholar 

  24. Macedo A, A. Orfao, A. Martinez, B. Vidriales, M.C. López-Berges, J.F. San Miguel. Immunophenotype of C-kit cells in normal human bone marrow: implications for the detection of minimal residual disease. Br.J.Haematol. 1995; 89: 338–341.

    Article  PubMed  CAS  Google Scholar 

  25. Macedo A, Orfao A, M. Gonzalez, B. Vidriales, M.C. López-Berges, A. Martinez, J.F. San Miguel. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies. Leukemia (In press).

    Google Scholar 

  26. Bartram CR. Detection of minimal residualleukemia by t h e polymerase chain reaction: potential implications for therapy. Clin.Chim.Acta 1993; 217: 75–83.

    Article  PubMed  CAS  Google Scholar 

  27. Potter MN, N.C.P. Cross, J.J.M. van Dongen, G. Saglio, A. Oakhill, C.R. Bartram, J.M. Goldman. Molecular evidence of minimal residual disease after treatment for leukaemia and lymphoma: an updated meeting report and review. Leukemia 1993; 7: 1302–1314.

    PubMed  CAS  Google Scholar 

  28. Ito Y, R. Wasserman, N. Galili, B.A. Reichard, S. Shane, B. Lange, G. Rovera Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia. J.Clin.Oncol. 1993; 11: 546–553.

    PubMed  CAS  Google Scholar 

  29. Beishuizen A, M.A.J. Verhoeven, E.R. van Wering, K. Hahlen, H. Hoojikaas, J.J.M. van Dongen. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood 1994; 83: 2238–2247.

    PubMed  CAS  Google Scholar 

  30. Kitchingman GR. Residual disease detection in multiple follow-up samples in children with acute lymphoblastic leukemia 1994; 8: 395–401.

    PubMed  CAS  Google Scholar 

  31. Sanchez I. J.F. San Miguel. Corral et al. Gene rearrangement in acute non-lymphoblastic leukemia. Correlation with morphological and immunophenotypic characteristics of blast cells. Br.J.Haematol. 1995; 89: 104–109.

    PubMed  CAS  Google Scholar 

  32. Lion T, T. Henn, A. Gaiger, P. Kahis, H. Dagner. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. Lancet 1993; 341: 275–276.

    Article  PubMed  CAS  Google Scholar 

  33. Lococo F, D. Diversio, P.D. Paudolfi et al. : Molecular evaluation of residual disease as predictor of relapse in acute promyelocytic leukemia. Lancet 1992; 340: 1437–1438.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Hematologia, Hospital Universitario de Salamanca, Spain

    J. F. San Miguel

  2. Department of Immunology, Erasmus University, Rotterdam, The Netherlands

    J. J. M. van Dongen

Authors
  1. J. F. San Miguel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. J. M. van Dongen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, University of Münster, Albert-Schweitzer-Strasse 33, 48145, Münster, Germany

    T. Büchner

  2. Department of Pediatrics, University of Münster, Albert-Schweitzer-Strasse 33, 48145, Münster, Germany

    G. Schellong , J. Ritter  & U. Creutzig ,  & 

  3. Department of Internal Medicine, University of Göttingen, Robert-Koch-Strasse 40, 37075, Göttingen, Germany

    W. Hiddemann  & B. Wörmann  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

San Miguel, J.F., van Dongen, J.J.M. (1997). Methods for Detection of Minimal Residual Disease. In: Büchner, T., Schellong, G., Ritter, J., Creutzig, U., Hiddemann, W., Wörmann, B. (eds) Acute Leukemias VI. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 38. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60377-8_51

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-60377-8_51

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64379-8

  • Online ISBN: 978-3-642-60377-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation